Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
First patient treated in dose-expansion portion of SpliceBio’s phase 1/2 ASTRA clinical trial | Ophthalmology Times
(Image Credit: AdobeStock/Ilya) SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial (NCT06942572) evaluating SB-007 for the treatment of Stargardt disease. SB-007 is an investigational dual adeno-associated virus (AAV) gene…
Glaucoma innovation: Eight themes to watch in 2026 | Ophthalmology Times
Glaucoma care is evolving through the integration of artificial intelligence, advanced procedures, and personalized treatment strategies. (Image credit: AdobeStock/thodonal) As the ophthalmology community observes Glaucoma Awareness Month this January, glaucoma specialists point to incremental integration of technologies that support earlier…
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab | Ophthalmology Times
(Image Credit: Adobe Stock/fotofabrika) Ollin Biosciences has announced positive topline results from its randomized, head-to-head phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo). The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or…
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA | Ophthalmology Times
Outlook Therapeutics, Inc. reported that the FDA has issued a complete response letter (CRL) concerning the resubmitted biologics license application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg).1,2 The letter noted that the agency cannot approve the application in its current form for the…
What changed in glaucoma care in 2025: Surgeon perspective | Ophthalmology Times
In a year-end conversation, Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care evolved as 2025 drew to a close. Framing the discussion as a…
Global trial equity: How LMIC data is reshaping US ophthalmology research | Ophthalmology Times
Incorporating data from low- and middle-income countries may help redefine how ophthalmology trials are designed, evaluated, and applied in practice (Image credit: AdobeStock/PUTRABATARA) Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins…
Comparing Aflibercept 8 mg and Faricimab in RVO | Ophthalmology Times
In this segment, the panel compares the pivotal QUASAR trial of aflibercept 8 mg in retinal vein occlusion (RVO) with the BALATON and COMINO trials evaluating faricimab. They note that all three studies demonstrated robust visual and anatomic improvements—typically gains…
Insights from Privotal Trials for Aflibercept (8 mg) in RVO | Ophthalmology Times
This segment explores emerging data on aflibercept 8 mg for retinal vein occlusion (RVO) and the evolving understanding of disease chronicity under anti-VEGF therapy. The panelists discuss the pivotal QUASAR trial, which uniquely combined CRVO and BRVO populations and demonstrated…
Achieving a new level of refractive precision: Surgical strategies | Ophthalmology Times
(Image Credit: AdobeStock) Even the most experienced cataract surgeons—armed with advanced diagnostic technologies, modern IOL power calculation formulas, and a meticulous surgical technique—encounter patients whose vision does not reach the intended refraction. A prospective analysis of about 9000 routine cataract…
FDA approvals in 2025: What changed and why it matters for ophthalmologists | Ophthalmology Times
Editor’s Note: This content was generated with the assistance of AI. From first-in-class pharmacologic therapies to next-generation retinal durability strategies and less invasive surgical platforms, 2025 emerged as a pivotal year for the ophthalmic pipeline. Over the past 12 months,…